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A ventilator strategy combining low tidal volume
ventilation, recruitment maneuvers, and high
positive end-expiratory pressure does not increase
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and may improve patient comfort
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Lisa D Burry7, Qi Zhou8, Maureen Meade2, for the Lung Open Ventilation Study Investigators
Abstract
Background: The Lung Open Ventilation Study (LOV Study) compared a low tidal volume strategy with an experimental
strategy combining low tidal volume, lung recruitment maneuvers, and higher plateau and positive end-expiratory
pressures (PEEP) in adults with acute respiratory distress syndrome (ARDS). Herein, we compared sedative, opioid, and
neuromuscular blocker (NMB) use among patients managed with the intervention and control strategies and clinicians'
assessment of comfort in both groups.
Methods: This was an observational substudy of the LOV Study, a randomized trial conducted in 30 intensive care
units in Canada, Australia, and Saudi Arabia. In 16 centers, we recorded daily doses of sedatives, opioids, and NMBs and
surveyed bedside clinicians about their own comfort with the assigned ventilator strategy and their perceptions of
patient comfort. We compared characteristics and outcomes of patients who did and did not receive NMBs.
Results: Study groups received similar sedative, opioid, and NMB dosing on days 1, 3, and 7. Patient comfort as assessed
by clinicians was not different in the two groups: 93% perceived patients had no/minimal discomfort. In addition, 92% of
clinicians were comfortable with the assigned ventilation strategy without significant differences between the two
groups. When clinicians expressed discomfort, more expressed discomfort about PEEP levels in the intervention vs control
group (2.9% vs 0.7%, P <0.0001), and more perceived patient discomfort among controls (6.0% vs 4.3%, P = 0.049). On
multivariable analysis, the strongest associations with NMB use were higher plateau pressure (hazard ratio (HR) 1.15; 95%
confidence interval (CI) 1.07 to 1.23; P = 0.0002) and higher daily sedative dose (HR 1.03; 95% CI 1.02 to 1.05; P <0.0001).
Patients receiving NMBs had more barotrauma, longer durations of mechanical ventilation and hospital stay, and higher
mortality.
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Conclusions: In the LOV Study, high PEEP, low tidal volume ventilation did not increase sedative, opioid, or NMB doses in
adults with ARDS, compared with a lower PEEP strategy, and appeared at least as comfortable for patients. NMB use may
reflect worse lung injury, as these patients had more barotrauma, longer durations of ventilation, and higher mortality.
Trial registration: ClinicalTrials.gov Identifier NCT00182195
Keywords: ARDS; Neuromuscular blocker; Sedation; Opioid; Mechanical ventilation; Clinician comfort
Background
Low tidal volume ventilation is a standard of care in adults
with the acute respiratory distress syndrome (ARDS) and
is associated with reduced mortality compared to trad-
itional tidal volumes [1]. Low tidal volume ventilation may
reduce minute ventilation with resultant patient discom-
fort and patient-ventilator asynchrony, and greater use of
sedation, opioids, and neuromuscular blockers (NMBs).
However, post hoc analyses of patients enrolled in two
participating centers of the original low tidal volume trial
did not detect differences in the dose or duration of seda-
tives and opioids between low tidal volume and control
groups [2,3].
Despite concerns about NMBs including the need for
deep sedation and the risk of ICU-acquired weakness [4],
results of a recent trial have renewed interest in the use of
NMBs in patients with ARDS. Papazian and colleagues
randomized 340 patients with early severe ARDS to receive
continuous infusions of cisatracurium besylate or placebo
for 48 h and observed a 30% relative reduction in adjusted
mortality risk in the cisatracurium-treated group, as well as
more ventilator-free days and no increase in the risk of
acquired paresis in the intensive care unit (ICU) [5].
The Lung Open Ventilation Study (LOV Study) was a
multicenter randomized trial that compared a standard
low tidal volume ventilation strategy with a novel strat-
egy designed to recruit the lung, combining low tidal
volumes, high positive end-expiratory pressure (PEEP),
and recruitment maneuvers in 983 adults with ARDS
[6]. The original publication reported no differences in
the proportion of patients receiving sedative, opioid, and
NMB infusions, or the duration of these infusions, but
did not provide detailed data about medication adminis-
tration, including specific medications and dosages.
Given the benefits of sedation minimization [7] and the
potential benefit of NMBs [5], it is important to better
understand the use of these medications in patients
managed with high PEEP, low tidal volume, and recruit-
ment maneuvers - a combination commonly used in
patients with ARDS.
In this substudy of the LOV Study, our objectives were
to 1) describe the types and doses of sedatives, opioids, and
NMBs administered to patients mechanically ventilated
using a high PEEP, low tidal volume and recruitment man-
euver strategy (intervention group) versus conventional
low tidal volume ventilation (control group); 2) describe
clinicians' assessment of comfort in patients randomized to
the two groups; and 3) compare characteristics and
outcomes of patients who did and did not receive NMBs.
We hypothesized that clinicians would have more concerns
about discomfort in the intervention group, resulting in
the use of higher doses of sedatives and opioids, because
they were managed with recruitment maneuvers and sig-
nificantly higher plateau pressures, PEEP, and I/E ratio [6].
Methods
Study design
The complete methods and results of the LOV Study have
been previously published [6]. This substudy of the LOV
Study was planned and initiated after 539 of 983 patients
had been enrolled in the primary study. For this substudy,
sedative, opioid, and NMB data were collected in 16
centers (13 in Canada, 2 in Australia, 1 in Saudi Arabia),
on 444 subsequent patients, between August 2000 and
March 2006. These data were collected retrospectively for
patients enrolled between August 2000 and January 2003,
and prospectively for patients enrolled after January 2003.
Clinician comfort questionnaires were completed for 417
patients. The research ethics board of each hospital
approved the trial (see Additional file 1 for ethics boards),
and a priori informed consent was obtained from substi-
tute decision makers.
Participants
The LOV Study included 983 patients ≥18 years of age
with acute respiratory distress syndrome, defined as new
respiratory symptoms within 28 days with bilateral radio-
graphic opacities, and a ratio of arterial oxygen tension to
inspired oxygen fraction (PaO2/FIO2) ≤250. We excluded
patients with left atrial hypertension as the cause of
respiratory failure, expected duration of mechanical venti-
lation <48 h, >48 h of eligibility, inability to wean from
nitric oxide, severe chronic respiratory or neuromuscular
disease, intracranial hypertension, morbid obesity (>1 kg/cm
body height), pregnancy, lack of commitment to life sup-
port, >50% anticipated 6-month mortality, and participation
in a confounding trial. Use of sedatives, opioids, and NMBs
was at the discretion of the ICU clinicians.
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Data collection and outcome measurements
Research personnel recorded demographic characteristics,
physiological data, and relevant laboratory data from
the 24 h preceding randomization. At baseline and daily,
we documented doses and route of administration of
all sedatives, opioids, NMBs, and three anti-psychotics
(haloperidol, risperidone, and olanzapine). At each center,
we documented whether sedation, analgesia, or NMBs were
administered using a local protocol.
For each of the first four study days, we administered an
anonymous, patient-specific questionnaire to physicians
and respiratory therapists, surveying their assessment of
patient comfort, manifestations of the patient's discomfort,
the clinician's own level of comfort with the ventilator
strategy, and reasons for their discomfort, where appropri-
ate (please see Additional file 1 for the questionnaire). We
collected these data for 417 consecutive patients enrolled
in the LOV Study after 13 June 2001.
Statistical analysis
We present data regarding doses of medications adminis-
tered on study days 1, 3, and 7 for 444 patients. Continu-
ous data are reported as mean and standard deviation
(SD), or median and interquartile range (IQR) when not
normally distributed. Categorical variables are reported as
frequency and percentage. We compared medication
doses and durations, and clinicians' assessment of patient
comfort in patients randomized to the intervention and
control groups. We also compared baseline characteristics
and outcomes of all 983 patients enrolled in the LOV
Study who received and did not receive NMBs. For the
comparisons of continuous data, we used Student's t test
if it was normally distributed or Wilcoxon's rank-sum test
if it was not normally distributed. For categorical data, we
used the chi-square test for the comparison, or Fisher's
exact test when the expected event count was less than 5.
All statistical tests were two-tailed, and a P value <0.05
was considered statistically significant.
To obtain hazard ratios (HRs) for time to NMB use, we
performed Cox regression analysis and used the marginal
model approach to account for variation due to clustering
by center. The independent variables included baseline
factors (age in 10-year increments, Acute Physiology and
Chronic Health Evaluation II (APACHE II) score in
5-point increments, sepsis, and ventilator strategy) and
time-dependent repeated measurements which reflected
the most recent values at each point in time (sedative daily
doses in 10 mg midazolam equivalent increments, opioid
daily doses in 10 mg morphine equivalent increments,
levels of PEEP and Pplateau, PaO2/FiO2 in 5-unit incre-
ments, tidal volume, and barotrauma). To calculate
midazolam equivalents, the following conversion was
used: 0.5 mg lorazepam = 1 mg midazolam; to calculate
morphine equivalents, the following conversion was used:
10 mg morphine = 100 mcg fentanyl = 2 mg hydromor-
phone [8]. Hazard ratios are presented with 95% confi-
dence intervals. Risk factors that had a strong association
(P <0.01) were considered significant.
Results
Study population
Table 1 shows baseline characteristics of the 444 patients
in this substudy. Among these patients, there were no
differences in baseline characteristics of patients ran-
domized to the intervention and control groups, nor
were there differences between patients in this substudy
and the entire LOV Study population.
Sedative, opioid, and antipsychotic administration
On days 1, 3, and 7, approximately 91%, 87%, and 78% of
patients received intravenous sedation, with similar pro-
portions in the two groups (Additional file 1: Table S1).
Midazolam was the most common sedative (61% to 78%
of patients on days 1, 3, and 7), followed by propofol (20%
to 28%) and lorazepam (9% to 16%); more than 75% of
patients had midazolam and propofol administered as
continuous infusions. Fewer than 2% of patients had
sedation managed using a protocol. There were no differ-
ences between groups in median daily sedative doses on
days 1, 3, and 7 (Table 2).
Table 1 Baseline characteristics
Characteristics Intervention group Control group
N =218 N =226
Age, mean (SD) 53.5 (16.2) 55.5 (16.6)
Female sex, n (%) 91 (41.7) 90 (39.8)
APACHE II score, mean (SD) 25.6 (7.9) 26.4 (7.8)
PaO2/FiO2, mean (SD) 145.5 (43.5) 149.2 (51.6)
Set PEEP, cm H2O, mean (SD) 11.2 (3.4) 10.9 (3.2)
Pplateau, cm H2O, mean (SD) 30.4 (5.6) 30.1 (6.1)
PaCO2, mean (SD) 43.0 (11.2) 42.1 (9.5)
pH, mean (SD) 7.4 (0.1) 7.4 (0.1)
Tidal volume, ml/kg PBW,
mean (SD)
8.4 (2.1) 8.2 (2.0)
Minute ventilation, mean (SD) 11.9 (3.6) 11.9 (3.9)
Glasgow Coma Score, mean (SD) 6.2 (3.9) 6.4 (4.0)
Hepatic failure/cirrhosis, n (%) 11 (5.1) 8 (3.5)
Chronic dialysis, n (%) 22 (10.1) 21 (9.3)
Corticosteroids, n (%) 52 (51.5) 49 (48.5)
Sedative infusions, n (%) 166 (76.2) 178 (78.8)
Opioid infusions, n (%) 150 (68.8) 162 (71.7)
Neuromuscular blockers, n (%) 42 (19.3) 39 (17.3)
In this table, we present baseline characteristics of all included patients. Data are
presented as n (%) or mean and standard deviation. APACHE II, Acute Physiology
and Chronic Health Evaluation II. Sedative infusions = benzodiazepines
and/or propofol.
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Table 2 Intravenous sedative and opioid administration on days 1, 3, and 7
Variables Day 1 Day 3 Day 7
Intervention Control P value Intervention Control P value Intervention Control P value
N =218 N =226 N =203 N =219 N =144 N =163
Any sedationa,
n (%)
199 (91.3) 208 (92.0) 0.96 178 (87.7) 192 (87.7) 0.99 115 (79.9) 127 (77.9) 0.68
Midazolam
mg, median (IQR) 92 (32 to 194) 81 (36 to 157) 0.30 118 (46 to 240) 101 (34 to 240) 0.20 107 (24 to 240) 193 (52.5 to 352) 0.06
n 172 178 145 162 94 100
Lorazepam
mg, median (IQR) 7 (3 to 19) 12 (4 to 35) 0.31 5 (2 to 12) 8 (2 to 32) 0.49 9 (3 to 24) 9 (2 to 48) 0.90
n 23 32 19 35 20 26
Propofol
mg, median (IQR) 1,040 (200 to 2,470) 860 (260 to 2,160) 0.48 1,300 (280 to 2,830) 1,340 (285 to 2,840) 0.69 1,180 (270 to 3,125) 1,758 (470 to 3,250) 0.98
n 50 49 55 44 41 33
Any opioidb, n (%) 182 (83.5) 193 (85.4) 0.74 161 (79.3) 180 (82.2) 0.45 104 (72.2) 120 (73.6) 0.78
Morphine
mg, median (IQR) 72 (124 to 176) 89 (25 to 178) 0.83 96 (40 to 240) 80 (32 to 212) 0.97 95 (24.5 to 237.5) 94 (26.5 to 249) 0.30
n 134 131 118 121 84 80
Fentanyl
mcg, median (IQR) 1,600 (690 to 3,225) 1,270 (550 to 3,100) 0.47 2,495 (495 to 4,350) 2,728 (760 to 4,800) 0.40 3,072 (1,335 to 4,100) 2,240 (580 to 5,200) 0.51
n 60 58 46 58 20 40
Hydromorphone
mg, median (IQR) 4 (4 to 4) 72 (8 to 97) 0.44 34 (2 to 65) 98 (40 to 136) 0.44 5 (5 to 5) 69 (49 to 88) 0.60
n 1 3 2 3 1 2
In this table, we present the percentage of patients receiving any sedation, any opioid, and median daily doses of sedatives and opioids in the two groups, on days 1, 3, and 7. The total N for each group at each
timepoint represents the number of patients for whom data was reported. Doses are presented as median and interquartile range (IQR). n represents the number of patients receiving the sedative/opioid agent on the
corresponding day. aSedation includes any of the following agents: lorazepam, midazolam, propofol, ketamine, clonazepam, and diazepam. bOpioids include morphine, meperidine, fentanyl, sufentanil, alfentanil,
and codeine.
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On days 1, 3, and 7, more than 70% of patients received
intravenous opioids, with the greatest frequency of use on
day 1 (Additional file 1: Table S2). Morphine was the most
common opioid (49% to 60% patients), followed by
fentanyl (14% to 27%) and hydromorphone (0.5% to 1.4%).
Morphine and fentanyl were administered as continuous
infusions to more than 75% and 90% of patients, respect-
ively. Fewer than 1% of patients had opioids managed
using a protocol. The overall proportion of patients receiv-
ing opioids was similar in both groups. There were no
significant differences in median daily opioid doses
between groups on days 1, 3, and 7 (Table 2).
On days 1, 3, and 7, fewer than 10% of patients received
an antipsychotic medication (haloperidol, risperidone, or
olanzapine), with similar proportions of patients and doses
in the intervention and control groups (Additional file 1:
Table S3).
Clinician comfort assessment
Clinicians completed 2,740 questionnaires for 417 pa-
tients, during the first four study days (Table 3). Clinicians
assessed patient comfort in both groups as similar. The
majority (>93%) perceived that patients had no or minimal
discomfort. When asked about manifestations of patient
discomfort, the most common response was ventilator
asynchrony for both groups. Patients in the control group
were more often perceived to have ventilator asynchrony
(10% vs 8%, P = 0.02) and diaphoresis (1% vs 0.3%,
P = 0.03). Clinicians indicated on 92.2% of surveys that
they were ‘not at all’ or ‘minimally’ uncomfortable with
the assigned ventilator strategy; clinician comfort was
similar between the two ventilation strategies. Of clini-
cians who expressed any discomfort about the assigned
strategy, the two most common concerns in both groups
were the need for large amounts of sedation or paralysis
(8.7% vs 6.1%, P = 0.01) and apparent patient discomfort
(6.0% vs 4.3%, P = 0.049); these concerns were greater in
control group patients. More clinicians expressed discom-
fort about high levels of PEEP in the intervention than
the control group (2.9% vs 0.7%, P <0.0001).
Neuromuscular blocker administration
On days 1, 3, and 7, approximately 26%, 20%, and 13% of
the 444 substudy patients received NMBs, with similar
proportions in the two groups (Additional file 1: Table
S4). Fewer than 2% of patients had NMBs managed using
a protocol. The most commonly used NMB was vecuro-
nium, followed by cisatracurium, rocuronium, and pan-
curonium; median daily doses of the three most
commonly used agents were similar in the two groups on
days 1, 3 and 7 (data not shown).
Table 4 shows baseline characteristics and outcomes of
all 983 patients enrolled in the LOV Study who received
and did not receive NMBs. Overall, 431 (43.8%) patients
received NMBs, and they were started on day 1 (median,
IQR 1 to 4 days). For these patients, the median number
of days receiving a NMB was 3 (IQR 1 to 5 days); both
the intervention and control groups received NMBs for
a similar number of days. At baseline, patients who
received NMBs were younger and had a higher severity
of illness, with higher APACHE II score, lower pH and
PaO2/FiO2, higher PEEP, higher plateau pressure, higher
PaCO2, and lower tidal volume. In Cox regression ana-
lysis of the 444 substudy patients (Table 5), higher daily
sedative dose (HR 1.03; 95% confidence interval (CI)
1.02 to 1.05; P <0.0001) and higher plateau pressure (HR
1.15; 95% CI 1.07 to 1.23; P =0.0002) were independently
associated with time to NMB use. Regarding outcomes,
patients who received NMBs had more barotrauma,
longer durations of mechanical ventilation and hospital
stay, and higher mortality.
Discussion
In this substudy of the LOV Study, we found that the
addition of high PEEP and recruitment maneuvers to a
low tidal volume ventilation strategy did not alter the
overall dosing or duration of sedatives, opioids, or NMBs,
compared with a low tidal volume strategy, despite higher
plateau pressures. While clinicians were generally com-
fortable with both ventilator strategies, our results suggest
that clinicians more frequently perceived patient discom-
fort in the control group, with more ventilator asynchrony
and, rarely, diaphoresis. In addition, they were more
frequently concerned about high amounts of sedation and
paralysis among control patients, contrary to our hypoth-
esis. Our assessment of NMB use among all patients in
the LOV Study showed that patients who received NMBs
were younger and had more severe ARDS and worse
outcomes, including more barotrauma, longer durations
of mechanical ventilation and hospital stay, and higher
mortality.
While low tidal volume ventilation is a standard of care
in the management of adult ARDS, the role for higher ver-
sus lower PEEP strategies is less clear. Three multicenter
trials assessing unique high-PEEP protocols did not ob-
serve clear benefit or harm with respect to patient survival
[6,9,10]. However, a subsequent individual patient data
meta-analysis of these trials found a statistically significant
reduction in mortality with higher PEEP among the sub-
group of patients with ARDS, rather than milder forms of
acute lung injury [11]. These findings suggest that a higher
PEEP strategy is likely as effective as a lower PEEP strategy
and perhaps superior for patients with more severe
disease. Our findings in this substudy of the LOV Study,
suggesting that bedside clinicians perceive more patient
discomfort with a lower PEEP strategy, provide additional
support for clinicians who perceive their patients will
benefit from a high-PEEP ventilation strategy in ARDS.
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Overall, clinicians were equally comfortable with the two
ventilator strategies and administered similar doses of
sedatives and analgesics to patients in the two groups.
Our results are also similar to a retrospective analysis of
the multicenter ALVEOLI trial, which randomized 549
patients with acute lung injury/ARDS to a high PEEP or a
lower PEEP strategy, and found no difference in survival
between the two groups [9,12]. In the ALVEOLI trial, the
compared ventilation strategies differed primarily with
respect to PEEP levels. In contrast, the two LOV Study
groups differed significantly with respect to more respira-
tory variables: PEEP levels, plateau pressures, I/E ratio,
and the use of recruitment maneuvers. In the ALVEOLI
trial, sedatives and opioids were used in more than 80% of
patients, in a similar proportion in both groups; however,
a higher proportion of patients in the lower PEEP group
received NMBs (45% vs 33%, P = 0.006) and for a longer
duration (1.1 vs 0.9 days, P = 0.008). The use of sedatives
and opioids, but not NMBs, was associated with longer
time on mechanical ventilation.
Over the last few decades, clinicians have avoided NMBs
in critically ill patients because of concerns regarding the
need for deep sedation, as well as the risk of ICU-acquired
weakness [4]. However, a recent trial in patients with
severe ARDS demonstrated potential benefits [5]. In this
multicenter, double blind trial, 340 patients with early
severe ARDS were randomized to receive cisatracurium
besylate or placebo for 48 h. After adjusting for the
pre-specified covariates of baseline PaO2/FiO2, Simplified
Acute Physiology II score, and plateau pressure, in
patients with a PaO2/FiO2 of less than 120, the mortality
rate was 30.8% in the cisatracurium group compared with
44.6% in the control group (HR 0.68; 95% confidence
interval 0.48 to 0.98; P = 0.04) - a 30% relative mortality
reduction. Additionally, the cisatracurium group had more
ventilator-free days and no increased incidence of ICU-
acquired weakness. Two systematic reviews of 431 pa-
tients in three randomized trials reported lower mortality,
more ventilator-free days, and less barotrauma in patients
treated with NMBs [13,14].
Table 3 Comfort assessment: perceptions of physicians and respiratory therapists
Intervention Control Relative risk (95%
confidence interval)
P value
N =1,297 N =1,443
How much discomfort is this patient experiencing? n (%) N =1,185 N =1,309
No discomfort 960 (81.0) 1,020 (77.9) 1.04 (0.99, 1.08) 0.06
Minimal discomfort 152 (12.8) 192 (14.7) 0.87 (0.72, 1.07) 0.18
Moderate, major, or extreme discomfort 73 (6.2) 97 (7.4) 0.83 (0.62, 1.11) 0.22
How does the patient's discomfort manifest? n (%) N =1,229 N =1,360
Air hunger 40 (3.3) 55 (4.0) 0.80 (0.54, 1.20) 0.29
Agitation 92 (7.5) 122 (9.0) 0.83 (0.64, 1.08) 0.17
Ventilator asynchrony 97 (7.9) 143 (10.5) 0.75 (0.59, 0.96) 0.02
Diaphoresis 4 (0.3) 14 (1.0) 0.32 (0.10, 0.96) 0.03
How uncomfortable are you with the ventilator strategy? n (%) N =1,186 N =1,308
Not at all 1,002 (84.5) 1,082 (82.7) 1.02 (0.99, 1.06) 0.24
Minimally 105 (8.9) 136 (10.4) 0.85 (0.67, 1.08) 0.19
Moderately 56 (4.7) 62 (4.7) 0.996 (0.70, 1.42) 0.98
Very 17 (1.4) 19 (1.5) 0.99 (0.52, 1.89) 0.97
Extremely 6 (0.5) 9 (0.7) 0.74 (0.26, 2.06) 0.56
What is the cause of your discomfort? n (%) N =1,223 N =1,357
High level of PEEP 35 (2.9) 10 (0.7) 3.88 (1.93, 7.81) <0.0001
Apparent patient discomfort 52 (4.3) 81 (6.0) 0.71 (0.51, 1.00) 0.049
Need for large amounts of sedation or paralysis 75 (6.1) 118 (8.7) 0.71 (0.53, 0.93) 0.01
Concerns of other bedside clinician 15 (1.2) 17 (1.3) 0.98 (0.49, 1.95) 0.95
Concerns of family 5 (0.4) 13 (1.0) 0.43 (0.15, 1.19) 0.10
In this table, we present results of the comfort assessments. Daily for the first 4 days after randomization, we administered an anonymous questionnaire to
physicians and respiratory therapists, asking about their assessment of the patient's discomfort related to the assigned ventilation strategy, the manifestation of
the patient's discomfort, the clinician's discomfort with the ventilator strategy, and the reasons for the clinician's discomfort (see Additional file 1 for the
questionnaire). This table represents 417 patients and 2,740 questionnaires; 2,322 (85%) of questionnaires were completed by physicians and 418 (15%) by
respiratory therapists. The median number of questionnaires per patient was 4 (IQR 4 to 8).
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This recent trial by Papazian and colleagues [5]
prompted us to further evaluate NMB use in the LOV
Study. We found that patients who received NMBs were
younger, had a higher APACHE II score, more baro-
trauma, longer durations of mechanical ventilation and
hospital stay, and higher mortality. Their worse out-
comes likely reflect greater illness severity, and it is not
possible to draw inferences about causality with respect
to the use of NMBs. In our multivariable analysis, we
identified higher plateau pressure and higher sedative
doses as independent determinants of NMB use, which
both likely reflect more severe ARDS.
To the best of our knowledge, this is the only study to
date which has evaluated clinician comfort and clinicians'
assessment of patient discomfort with the assigned
ventilator strategies. Strengths of this study are the daily
prospective recording of sedative, analgesic, and NMB
administration in relation to carefully protocolized ventila-
tion strategies, and real-time assessment of perceived
patient comfort associated with these exposures during
the conduct of a trial. The sample size is large compared
with previous studies, and we conducted multivariable
regression analysis to address confounding associations
with NMBs. The multicenter design enhances the gene
ralizability of these findings. This study has several limita-
tions. The administration of sedatives, opioids, and NMBs
was managed by unblinded ICU clinicians rather than
protocolized, and we have no information about the use of
sedation or pain scales, delirium, NMB monitoring, or
ICU-acquired weakness in this study. The more frequent
clinician perception of ventilator asynchrony in the con-
trol group may relate to the use of volume-assist control
mode, compared with pressure control mode in the inter-
vention group [15].
Conclusions
Patients with ARDS are commonly managed with a venti-
lator strategy that includes low tidal volume, high PEEP,
and recruitment maneuvers. In the LOV Study, the use of
such a strategy was not associated with more sedative,
opioid, or neuromuscular blocker use, nor with higher
doses, compared with low tidal volume ventilation. Over-
all, bedside clinicians were equally comfortable with these
Table 4 Baseline characteristics and outcomes of patients
who received and did not receive neuromuscular blockers
Variables NMB No NMB P value
n = 431 n = 552
Baseline characteristics
Age, years, mean (SD) 54.4 (16.7) 56.9 (16.3) 0.02
Female sex, n (%) 165 (38.3) 229 (41.5) 0.31
APACHE II score, mean (SD) 26.7 (7.3) 24.3 (7.9) <0.0001
PaO2/FiO2, mean (SD) 132.0
(48.5)
154.6
(46.3)
<0.0001
Set PEEP, cm H2O, mean (SD) 12.0 (3.5) 10.7 (3.1) <0.0001
Pplateau, cm H2O, mean (SD) 30.9 (6.0) 28.7 (5.4) <0.0001
PaCO2, mean (SD) 44.2 (11.1) 40.7 (8.4) <0.0001
pH, mean (SD) 7.35 (0.08) 7.38 (0.08) <0.0001
Tidal volume, ml/kg PBW, mean
(SD)
8.2 (2.2) 8.6 (2.1) 0.01
Minute ventilation, l/min, mean (SD) 11.6 (3.5) 11.4 (3.4) 0.20
Barotrauma, n (%) 19 (4.4) 17 (3.1) 0.27
Hepatic failure/cirrhosis, n (%) 18 (4.2) 26 (4.7) 0.69
Chronic dialysis, n (%) 34 (7.9) 62 (11.2) 0.08
Interventions and outcomes
Corticosteroids during first 28 days,
n (%)
227 (52.7) 183 (33.2) <0.0001
Mechanical ventilation, days,
median (IQR)
14 (8 to
23)
8 (5 to
12)
<0.0001
Hospital stay, days, median (IQR) 24 (14 to
44)
20 (11 to
37)
0.01
Death during first 28 days, n (%) 168 (37.0) 131 (23.7) <0.0001
Death in ICU, n (%) 191 (44.3) 132 (23.9) <0.0001
Death during mechanical
ventilation,
n (%)
185 (43.5) 119 (22.1) <0.0001
Barotraumaa, n (%) 93 (21.6) 69 (12.5) 0.0001
In this table, we compare baseline characteristics and outcomes in all 983
patients enrolled in the LOV Study according to whether they received
neuromuscular blockers (NMBs) or not. SD, standard deviation; APACHE II,
Acute Physiology and Chronic Health Evaluation II; MOD, multiple organ
dysfunction; PEEP, positive end-expiratory pressure; PBW, predicted body
weight; ICU, intensive care unit. aRegardless of baseline status of barotrauma;
34 of 93 patients developed barotrauma after NMB administration.
Table 5 Cox's proportional-hazards regression analysis -
time to neuromuscular blocker use as the outcome and
stratified by center
Adjusted HR (95% CI) P value
Baseline variables
Age, 10-year increase 1.01 (0.87, 1.17) 0.92
APACHE II score, 5-point increase 1.66 (1.04, 2.66) 0.04
Intervention versus control 1.17 (0.32, 4.30) 0.82
Sepsis 1.00 (0.51, 1.97) 0.99
Time-dependent variables
Sedative doses, 10-mg increase 1.03 (1.02, 1.05) <0.0001
Opioid doses, 10-mg increase 1.01 (0.999, 1.02) 0.07
PEEP 0.88 (0.70, 1.11) 0.28
Pplateau 1.15 (1.07, 1.23) 0.0002
PaO2/FiO2, 5-point increase 1.05 (1.03, 1.08) 0.03
Tidal volume (ml/kg PBW) 0.99 (0.67, 1.47) 0.95
Barotrauma 8.54 (1.17, 62.09) 0.03
In this table, we present the multivariable Cox regression results. Both baseline
and time-dependent variables were considered. APACHE II, Acute Physiology
and Chronic Health Evaluation II. Sedative doses were expressed in midazolam
equivalents, and opioid doses were expressed in fentanyl equivalents.
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two ventilator strategies though they perceived more
patient discomfort with the lower PEEP strategy. Patients
who received NMBs had longer lengths of stay and higher
mortality, likely reflecting their greater severity of illness.
Additional file
Additional file 1: Supporting information. A file showing the research
ethics boards of institutions that approved the study, the 4-day comfort
assessment form, and four supplementary tables.
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